Genmab (ADR) (GMAB)
Develops antibody medicines through partner royalties, co-commercialization, and a wholly owned oncology portfolio.
$35.01
vs last close−0.21 (−0.60%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 31.85% | 204.85M ADS | |
|---|---|---|---|
| 306 holders · as of Jun 30, 2026 | |||
| Other | 68.15% | 438.23M ADS | |
| remainder | |||
643.08M ADS (1 ADS = 0 ordinary shares) as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This company has 2 share classes; every stake here is a share of the whole company.
13F, as of Jun 30, 2026
306 holders · 102.42M shares · 50 new positions · 152 increased · 102 reduced · 33 closed
| Holder | Shares | % of company | Chg q/q | Filed |
|---|---|---|---|---|
| Paradigm Biocapital Advisors LP | 13.13M | 2.04% | +5.17M | Aug 14, 2026 |
| Orbis Allan Gray Ltd | 11.37M | 1.77% | −1.56M | Aug 14, 2026 |
| AllianceBernstein L.P. | 8.64M | 1.34% | −912.3K | Aug 14, 2026 |
| Deerfield Management Company, L.P. (Series C) | 6.87M | 1.07% | +4.40M | Aug 14, 2026 |
| Deep Track Capital, LP | 5.65M | 0.88% | +1.99M | Aug 14, 2026 |
| Arrowstreet Capital, Limited Partnership | 4.98M | 0.77% | 0 | Aug 13, 2026 |
| BlackRock, Inc. | 4.67M | 0.73% | +134.7K | Aug 7, 2026 |
| Sofinnova Investments, Inc. | 4.05M | 0.63% | +3.29M | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 5.60% | 3.71M | 13G | Apr 23, 2025 |
| Orbis Investment Management Ltd | 5.50% | 3.55M | 13G | May 15, 2026 |
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.